Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Dana Classic Fragrances sale

This article was originally published in The Rose Sheet

Executive Summary

Letter of intent is signed by Dana Classic Fragrances, a company owned by New Dana Perfumes CEO Isaac Cohen, to purchase firm's fragrance portfolio including Tabu, Canoe, English Leather, Love's Baby Soft and British Sterling. Upon closing, Dana Classic Fragrances and Cohen's existing company Intermarketing Group will both become subsidiaries of IMG Holdings, a family of companies that sells Dana perfumes in Canada, Spain and Mexico. Cohen will serve as CEO of the combined entities. New Dana Perfumes was formed in 1999 by an investment affiliate to purchase the assets of the bankrupt Renaissance Cosmetics. After the sale, New Dana Perfumes will continue to own and operate its non-fragrance affiliate New Cosmar, which markets Cosmar, Frills and Nat Robbins...

You may also be interested in...

Keeping Track: Quick Trips From Breakthrough Designation To Market

Phase III data earns a breakthrough therapy designation for Resverlogix’ apabetalone; previous companies to follow that strategy swiftly advance to NDA submission, as seen with Novartis’ capmatinib and Seattle Genetics’ tucatinib.

Breakthrough Therapy Designations: Phase II Data Is Sweet Spot For US FDA Award

Pink Sheet analysis finds that evidence from early-stage trials supports most BTD requests, but about three in 10 designations are granted on the basis of pivotal-stage data.

Medicare-For-Hmmm: A Year Of House Hearings Show Democratic Disunity

Four House hearings show how far away even many Democrats are from supporting a single payer system in the US.




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts